Kornimate/medical-research-clean huggingface dataset:
web based social media technology to improvement in adherence to dual antiplatelet therapy following drug-eluting stent implantation

Conditions: Coronary Disease

Summary: few studies have attempt to improve dapt adherence through social media. the investigators will explore the prevalence of dapt discontinuation and prove the hypothesis that using social media will improve dapt adherence among patients requiring dapt following des implantation.

dual antiplatelet therapy (dapt) is frequently discontinued after drug-eluting stent (des) implantation, which could lead to many major adverse cardiovascular events (maces). social media have been proven effective in improving lifestyles and blood pressures control, but few studies have attempt to improve dapt adherence through social media.therefore, eligible patients will be enrolled through scanning qr code and randomized in a 1:1 ratio to an intervention group or control group with 12 months of follow-up.the investigators will find out the prevalence of dapt discontinuation and prove the hypothesis that using social media will improve dapt adherence among patients requiring dapt following des implantation..

Eligibility criteria:
inclusion criteria: * aged ≥18 years * diagnosed chd and underwent des implantation * provide written informed consent exclusion criteria: * pregnancy * malignant tumor or end-stage disease with a life expectancy of \<1 year; * refusal to use social media * refusal to provide written informed consent for this study

Keywords: dual antiplatelet therapy mobile health discontinuation rate drug-eluting stent implantation randomized controlled trial
clag+ven vs clag in the treatment of relapsed/refractory aml

Conditions: Relapsed/Refractory AML

Summary: this is a multicenter, prospective, randomized controlled clinical study comparing the efficacy and safety of clag+ven and clag regimens in relapsed/refractory(r/r) aml.

the efficacy and prognosis of relapsed/refractory(r/r) aml are very poor, and there is no standard chemotherapy regimen were defined for r/r aml. cladribine, a purine analogue, exerts cytotoxic, proapoptotic, and antiproliferative effects on aml cells. previous studies have confirmed the efficacy of cladribine in the treatment of r/r aml, with a response rate of 30-45%.our previous experience has shown that clag in combination of venetoclax are effective with tolerable toxicity profiling. however, there is a lack of multicenter, prospective, randomized controlled trials to further confirm the results. therefore, a clinical study is planned to evaluate the efficacy and safety of clag+ven compared to clag in r/r aml who were eligible for intensive therapy.

Eligibility criteria:
inclusion criteria: 1. diagnosed of aml according to the world health organization (who) classification. 2. all patients should aged 18 to 65 years. 3. diagnosed of relapsed and refractory aml, according to the guidelines for diagnosis and treatment of relapse /refractory acute myelogenous leukemia in china（2023） 4. diagnostic criteria for relapsed aml: leukemia cells reappear in the peripheral blood or primitive cells in the bone marrow ≥ 5% (excluding other reasons such as bone marrow regeneration after consolidation chemotherapy) after cr, or leukemia cell infiltration appears outside the marrow. 5. diagnostic criteria for refractory aml: the newly diagnosed patients who failed to respond to two courses of standard treatment; patients who relapsed within 12 months after consolidation intensive therapy; patients who relapsed after 12 months and failed to respond to conventional chemotherapy; patients with two or more recurrences; patients with persistent extramedullary leukemia. 6. the score of eastern cooperative oncology group (ecog) is 0-2. 7. renal function: creatinine clearance rate ≥ 30ml/min. 8. liver function: alt\<5 times normal value, bilirubin\<3 times normal value. 9. predicted survival ≥ 3 months. 10. able to accept oral venetoclax. 11. sign an informed consent form and be able to understand and follow the procedures required by this protocol. exclusion criteria: 1. diagnosed of acute promyelocytic leukemia (aml-m3) 2. patients with central nervous system (cns) invasion. 3. cardiac function \< grade 2. 4. known human immunodeficiency virus (hiv) infection. 5. other clinically significant uncontrolled conditions, including but not limited to: a. uncontrolled or active systemic infections (viruses, bacteria, or fungi); b. chronic hepatitis b virus (hbv) or hepatitis c virus (hcv) requiring treatment; c. secondary tumors requiring active treatment. 6. allergy to experimental drugs. 7. pregnant and lactating women. 8. patients who ineligible for the study according to the investigator's assessment.
haemodynamic abnormalities recorded with cardiac catheterization along with body's surface micro-accelerometers (kt-kcg)

Conditions: Heart Failure; Pulmonary Hypertension

Summary: the ballistocardiography (bcg) and the seismocardiography (scg) are old techniques recording the vibrations at the skin level generated by the acceleration and displacement of the blood and cardiac mass at each cardiac contraction. the former records the acceleration near the subject's center of mass, the latter at the local chest wall. so far, the unclear physiological origin of those acceleration signals has led to important ambiguities in their scientific and clinical interpretation. therefore, several ongoing studies would aim to highlight the physiological genesis of those acceleration-induced signals. indeed, the main objective of this study is to correlate the bcg and scg signals recorded at the body surface with several haemodynamic parameters recorded invasively during a cardiac catheterisation, pulmonary pressure, wedge pressure, cardiac output to cite a few.

patients suffering from severe heart failure regardless of the etiology will undergo a cardiac catheterization as required by their medical condition. the scg and bcg signals will be recorded simultaneously to the catheterization by the mean of an unintrusive and friendly device consisting of two houses, the first one placed on sternum and the second one in the lumbar column. the device will record a continuous tracing synchronized with the intracavitary pressure profiles recorded during the invasive procedure.

Eligibility criteria:
inclusion criteria: * age 18 y.o. to 80 y.o. * heart failure exclusion criteria: * left ventricle assistance device * refused participation

Keywords: intracavitary pressure ballistocardiography seismocardiography microaccelerations kinetic energy
presepsin as detective marker of sepsis in immunodeficiency icu patients

Conditions: Sepsis; Immune Deficiency

Summary: this is an observational study to evaluate the diagnostic and prognostic value of presepsin in the critically-ill immunocompromise patients.


Eligibility criteria:
inclusion criteria: * male or female aged ≥ 19 years * appropriate clinical data to enable classification into sepsis * written informed consent by the patient or legally authorized representative * critical illness consistent with sepsis, to be enrolled within 24 hours of presentation exclusion criteria: * no informed consent * a patient who is judged to be unable to make a voluntary decision by understanding information about this research due to cognitive vulnerability
e7050 in combination with cetuximab versus cetuximab alone in the treatment of platinum-resistant squamous cell carcinoma of the head and neck

Conditions: Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

Summary: the purpose of this study is to determine whether participants with platinum-resistant squamous cell carcinoma of the head and neck (scchn) who receive either e7050 administered with cetuximab or cetuximab alone experience greater benefit.

this open-label, multicenter, randomized study will consist of a phase 1b: a safety run-in period with 3 ascending doses of e7050 in combination with cetuximab; and a phase 2 portion: a randomized 2-arm period. approximately 95 participants with platinum-resistant squamous cell carcinoma of the head and neck will be enrolled in the study (10-15 participants in the phase 1b portion and 80 participants in the phase 2 portion). participants will only participate in either the phase 1b or the phase 2 portion of the study. in the phase 2 portion, participants will receive study treatment (e7050 plus cetuximab or cetuximab alone) for approximately six 28-day cycles (24 weeks). beyond 24 weeks, participants who are experiencing clinical benefit may continue e7050 plus cetuximab, cetuximab alone or e7050 alone (arm 1), or may continue cetuximab alone (arm 2), depending on the original randomization treatment arm, for as long as clinical benefit is sustained and the treatment is well tolerated.

Eligibility criteria:
inclusion criteria: * platinum-resistant (defined as failure to respond to treatment with a platinum agent or recurrence of disease after initial response to platinum within 12 months of completing therapy), locally advanced, recurrent and/or metastatic scchn, which is untreatable by surgical resection or radiation therapy * eastern cooperative oncology group performance status (ecog ps) of 0-2 * blood pressure must be well-controlled. participants must have no history of hypertensive crisis or hypertensive encephalopathy; adequate end organ function exclusion criteria * nasopharyngeal tumors * previously received e7050, anti-angiogenic therapy, or anti-epidermal growth factor receptor (egfr) therapy (prior anti-angiogenic/egfr therapy is permitted in phase 1b only. prior cetuximab is permitted if administered in combination with radiation * presence of brain metastases, unless the participant has received adequate treatment at least 4 weeks prior to randomization, and is stable, asymptomatic, and off steroids for at least 4 weeks prior to randomization * palliative radiotherapy is not permitted throughout the study period * clinically significant hemoptysis * serious non-healing wound, ulcer, or active bone fracture * major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to day 1, or anticipation of need for a major surgical procedure during the course of the study * clinically significant gastrointestinal bleeding within 6 months prior to first dose.

Keywords: cancer head and neck squamous cell carcinoma of the head and neck phase 1b phase 2
anticoagulation in gastroesophageal varices and jak2 mutation

Conditions: Gastroesophageal Varices; JAK2 Mutation; Myeloproliferative Neoplasm

Summary: myeloproliferative neoplasms (mpns), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, may lead to gastroesophageal varices. the quality of life, morbidity, and mortality of mpn patients mainly depend on disease-related symptoms, thromboembolic and hemorrhagic complications. previous studies have shown that jak2 v617f has a prominent role in vascular risk and mpn-associated gastroesophageal varices. the aim of this study is to evaluate the efficacy of anticoagulation in patients with jak2 mutation and gastroesophageal varices.


Eligibility criteria:
inclusion criteria: * male or female patients aged 18-75 * diagnosed as portal hypertension by contrast-enhanced computed tomography * diagnosed as jak2 positive exclusion criteria: * not had portal contrast-enhanced computed tomography * not had jak2 mutation test * other factors judged by the investigator that may affect the safety of the subject or the compliance of the trial. such as serious illnesses (including mental illness) that require combined treatment, serious laboratory abnormalities, or other family or social factors

Keywords: portal hypertension gastroesophageal varices jak2 mutation myeloproliferative neoplasm
the role of biomarker in serum, cerebrospinal fluid and parenchyma in the context of aneurysmal subarachnoid hemorrhage.

Conditions: Aneurysmal Subarachnoid Hemorrhage

Summary: the aim of this study is to improve the usability of biomarkers for the timely prediction of new complications following a cerebral hemorrhage, especially in combination with invasive, functional and local measurements for patients with aneurysmal subarachnoid hemorrhage (sah). based on analyzed biomarker profiles the chosen therapy efforts are assessed in their immediate and longer-term effectiveness.


Eligibility criteria:
inclusion criteria: * male or female, age ≥ 18 years * signed consent for participation in the study * signed consent for further analysis of the samples collected during the clinical routine * in-patients exclusion criteria: * female or male patient \<18 years * pregnancy, lactation * lack of signed informed consent for participation in the study * lack of signed consent for the further analysis of the samples collected during the clinical routine * taking a study drug within the last thirty days * simultaneous participation in another clinical trial (except participation as control group) * persons who are in a dependent relationship or employment with the sponsor or investigator * persons housed for a judicial or administrative order in an institution

Keywords: aneurysmal subarachnoid hemorrhage (ash) biomarker
posterior cingulate function in persons with risk factors for alzheimer's disease

Conditions: Magnetic Resonance Imaging; Alzheimer's Disease; Dementia; Adult Children; Risk

Summary: the purpose of this study is to use fmri techniques to explore a certain part of the brain associated with alzheimer's disease known as the posterior cingulate. determining the functionality of this brain region may help us diagnose ad more accurately, thus allowing earlier treatment.

the posterior cingulate is a key brain region suggested by recent studies to be affected in people at risk for alzheimer's disease (ad). because the pc is affected very early in the course of ad and the region may have reduced function even prior to the onset of symptoms, further understanding of its functional role and its relationship to other brain regions may be helpful in detecting ad earlier and in monitoring disease progression and treatment. this project examines the role of the pc and its connections to other brain regions using functional magnetic resonance imaging (fmri), a technique that allows us to examine the brain at work during tests of memory and decision-making. the main goal is to see if functional connections between brain regions are modulated by risk for ad.

Eligibility criteria:
inclusion criteria: * cognitively healthy * (controls only) parents survived past age 70 and did/do not have memory problems. exclusion criteria: * claustrophobia * metallic or electronic implants
reliability and validity of the dt balance test in patients with tka

Conditions: Knee Injuries and Disorders; Osteo Arthritis Knee

Summary: the ability to perform a cognitive task while walking simultaneously is essential in real daily life. however, the psychometric properties of dual-task walking tests have not been well established in patients undergoing total knee arthroplasty (tka). the aim of study assess the test-retest reliability and validity of dual conditions tug, 3mbwt, 8fwt nad 4sst in patients with tka.


Eligibility criteria:
inclusion criteria: tka - exclusion criteria: revision knee arthroplasty -

Keywords: total knee arthroplasty dual test, timed up and go reliability
evaluate the prognostic significance of changes in the systemic immune-inflammation index in patients with agc treated with ici therapy.

Conditions: Immunotherapy Gastrict Cancer; Inflammation Biomarkers; Gastric Cancers

Summary: the siir during neoadjuvant therapy can serve as a specific biomarker for predicting the efficacy of immunotherapy in patients with advanced gastric cancer.

a total of 410 patients with advanced gastric cancer treated with neoadjuvant chemotherapy (nac group, 178) or immunotherapy (icis group, 232) were enrolled in two tertiary referral centers. the siir (\[siipost-treatment - siipre-treatment\] / siipre-treatment) was calculated. the diagnostic threshold for siir was set at the median value (-0.3) a joint model based on longitudinal trajectory and time-to-event analysis was used to assess the correlation between siir and the risk of death in patients with advanced gastric cancer.

Eligibility criteria:
inclusion criteria: (1) preoperative clinical staging of ct2-4nxm0; (2) primary gastric adenocarcinoma confirmed via pathology; (3) no distant metastasis to the liver, lungs, or abdominal cavity as confirmed through preoperative chest x-ray or chest ct, abdominal ultrasound, and abdominal ct; (4) all patients received neoadjuvant therapy, followed by gastrectomy. exclusion criteria: we excluded patients under 18 or over 80, those with distant metastasis, remnant gastric cancer, prior radiotherapy, other malignancies, abdominal surgery history (except laparoscopic cholecystectomy), recent unstable angina, myocardial infarction, cerebrovascular accidents, or those requiring emergency surgery due to disease progression

Keywords: inflammation index gastric cancer immunotherapy
development of resistance mutations in pregnant hiv-positive (+) women following perinatal antiretroviral therapy in israel

Conditions: HIV Infections

Summary: it has been shown that treatment of hiv-positive women with antiretroviral medication during pregnancy reduces the risk of hiv transmission to the child. however, such treatment could lead to the selection of resistant virus strains in the mother. the object of this study is to check hiv+ pregnant women for resistance mutations in hiv before and after the antiretroviral therapy they receive during pregnancy. hiv-positive newborns will also be tested, to see if a resistant virus strain was transmitted from mother to child.

the project will be performed in collaboration with the israeli national hiv reference center laboratory, which maintains a national bank of hiv-positive blood samples, and with hiv/aids treatment centers located throughout israel. an initial survey will identify retrospectively those hiv+ women who were given antiretroviral therapy while pregnant and stopped treatment after delivery. the list of hiv+ deliveries over the past five years in each participating hospital will be reviewed, and all hiv-positive women who received antiretroviral treatment during pregnancy will be invited to participate in the study project. women who are currently pregnant, or become pregnant during the study, will be invited to participate when pregnancy is diagnosed. after obtaining informed consent, two blood samples will be obtained: one before the initiation of perinatal treatment, and the other following delivery. (due to technical limitations, only samples with viral loads above 1000 cp/ml can be genotyped. it is expected that hiv loads will rise following cessation of antiretroviral treatment, and that almost all samples will be eligible for resistance testing.) in addition, after obtaining maternal informed consent, samples from newborns infected perinatally with hiv will also be tested for resistance mutations, and these will be compared with the resistance pattern found in the mother. the samples obtained will be tested for genotypic resistance mutations. the results will be transmitted to the treating physician to assist in choice of antiretroviral therapy for the women and their children, if needed. the data will also be used to establish a national database to evaluate and improve existing protocols for perinatal antiretroviral treatment, and will be used to contribute to international databases of hiv resistance. all resistance data, except that given to the health care provider(s), will be transmitted without additional identifying information.

Eligibility criteria:
inclusion criteria: 1. hiv-positive women currently pregnant or with a past pregnancy in israel 2. blood/plasma samples available before and/or after perinatal antiretroviral treatment (before or during pregnancy if not treated) 3. hiv viral load in the samples adequate for resistance testing (approximately 1000 copies/ml) 4. informed consent obtained exclusion criteria: 1. samples not available or inadequate viral load 2. informed consent not obtained

Keywords: pregnancy hiv-positive hiv resistance hiv
effectiveness of exergaming in adittion to conventional treatment for physical therapy in people with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the present study aims to evaluate the effectiveness of two different exergaming systems in addition to conventional treatment on physical functional capacity, balance, muscle strength, spasticity in lower limbs and quality of life compared to an isolated conventional intervention in patients with multiple sclerosis. the secondary aim will be to compare the differences between both exergaming groups.

multiple sclerosis is a chronic autoimmune inflammatory disease of the central nervous system, which produces demyelination and axonal damage in the brain and spinal cord. since there is currently no treatment for this condition, the goal of rehabilitation is to assist people with their manifestations. over the last decade, exergaming with commercial consoles has demonstrated potential benefits in managing motor and functional impairments. however, new videogame strategies and assessment in randomized controlled trials are necessary to obtain significant results in different outcomes. the hypothesis is that the exergaming systems in addition to conventional treatment will show statistically significant improvements on motor skills, spasticity, and quality of life results compared to conventional therapy alone. therefore, this project aims to evaluate the effectiveness of two different exergaming systems in addition to conventional treatment on physical functional capacity, balance, muscle strength, spasticity in lower limbs and quality of life compared to an isolated conventional intervention in patients with multiple sclerosis. the investigators here design a multi-center, assessor-blind, 24-weeks, randomized controlled trial protocol. the achievement of the present project would serve to analyze the benefits of an alternative exercise program in the motor and functional rehabilitation program of multiple sclerosis patients and to identify the subjects in whom the benefits would be greater and whose implementation would have greater priority.

Eligibility criteria:
inclusion criteria: (i) diagnosis of ms in any of its types (clinically isolated syndrome, relapsing-remitting ms, primary progressive ms or secondary progressive ms) based on the mcdonald criteria. (ii) age over 18 years. (iii) mini-mental state examination score \> 19 points. (iv) score on the expanded disability status scale (edss) under 7.0 points. exclusion criteria: (i) diagnosis of another disease that affects balance and/or coordination. (ii) exacerbation or steroid treatment in the 30 days prior to inclusion in the study. (iii) presence of visual deficits.

Keywords: multiple sclerosis exergaming nintendo wii fit nintendo ring fit adventure physical therapy randomized controlled trial neurological rehabilitation